Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 6, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2015-03-27
DOI
10.3389/fimmu.2015.00127
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors
- (2015) Thibault Voron et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abstract A37: Immunization of cutaneous melanoma patients with the allogeneic cell vaccine CSF-470 enhances immune infiltration of metastatic lesions and would favor subsequent response to Vemurafenib
- (2015) Mariana Aris et al. Cancer Immunology Research
- Abstract CT104: Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma(MEL): Correlation of tumor PD-L1 expression with outcome
- (2015) Adil I. Daud et al. CANCER RESEARCH
- Peritumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control?
- (2014) I. Chevolet et al. BRITISH JOURNAL OF DERMATOLOGY
- Persistence of CTL Clones Targeting Melanocyte Differentiation Antigens Was Insufficient to Mediate Significant Melanoma Regression in Humans
- (2014) Smita S. Chandran et al. CLINICAL CANCER RESEARCH
- CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire
- (2014) L. Robert et al. CLINICAL CANCER RESEARCH
- OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy
- (2014) Yannick Bulliard et al. IMMUNOLOGY AND CELL BIOLOGY
- Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
- (2014) Xiaozhou Fan et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Expression of programmed death receptor ligand 1 in melanoma may indicate tumor progression and poor patient survival
- (2014) Junna Oba et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
- (2014) Matthew M. Gubin et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response
- (2014) P. Kvistborg et al. Science Translational Medicine
- Improved Survival with T Cell Clonotype Stability After Anti-CTLA-4 Treatment in Cancer Patients
- (2014) E. Cha et al. Science Translational Medicine
- Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies
- (2014) Andrew J.S. Furness et al. TRENDS IN IMMUNOLOGY
- PD-L1 Expression in Melanocytic Lesions Does Not Correlate with the BRAF V600E Mutation
- (2014) N. Rodi et al. Cancer Immunology Research
- Cytotoxic T Lymphocyte Antigen-4 Blockade Enhances Antitumor Immunity by Stimulating Melanoma-Specific T-cell Motility
- (2014) T. Pentcheva-Hoang et al. Cancer Immunology Research
- Pretreatment Serum VEGF Is Associated with Clinical Response and Overall Survival in Advanced Melanoma Patients Treated with Ipilimumab
- (2014) J. Yuan et al. Cancer Immunology Research
- Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
- (2014) F. S. Hodi et al. Cancer Immunology Research
- Control of the Adaptive Immune Response by Tumor Vasculature
- (2014) Laetitia Mauge et al. Frontiers in Oncology
- Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
- (2013) Christiane Meyer et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy
- (2013) Y. Huang et al. CANCER RESEARCH
- The density and type of MECA-79-positive high endothelial venules correlate with lymphocytic infiltration and tumour regression in primary cutaneous melanoma
- (2013) Gabriela Avram et al. HISTOPATHOLOGY
- Deciphering and Reversing Tumor Immune Suppression
- (2013) Greg T. Motz et al. IMMUNITY
- Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies
- (2013) Yannick Bulliard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
- (2013) Tyler R. Simpson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
- (2013) Rikke B. Holmgaard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- High Endothelial Venule Blood Vessels for Tumor-Infiltrating Lymphocytes Are Associated with Lymphotoxin -Producing Dendritic Cells in Human Breast Cancer
- (2013) L. Martinet et al. JOURNAL OF IMMUNOLOGY
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
- (2013) S. Spranger et al. Science Translational Medicine
- Increased Frequency of ICOS+ CD4 T Cells as a Pharmacodynamic Biomarker for Anti-CTLA-4 Therapy
- (2013) D. Ng Tang et al. Cancer Immunology Research
- Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
- (2013) M. J. Selby et al. Cancer Immunology Research
- Immunotherapy of cancer in 2012
- (2012) John M. Kirkwood et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Neogenesis of Lymphoid Structures and Antibody Responses Occur in Human Melanoma Metastases
- (2012) Arcadi Cipponi et al. CANCER RESEARCH
- VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer
- (2012) M. Terme et al. CANCER RESEARCH
- Suppressing T cell motility induced by anti–CTLA-4 monotherapy improves antitumor effects
- (2012) Maria Grazia Ruocco et al. JOURNAL OF CLINICAL INVESTIGATION
- Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2
- (2012) Tadashi Yokosuka et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
- (2012) Kim Margolin et al. LANCET ONCOLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
- (2012) Y. Huang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- Melanoma Vaccines and Modulation of the Immune System in the Clinical Setting: Building from New Realities
- (2012) Florencia Paula Madorsky-Rowdo et al. Frontiers in Immunology
- High endothelial venules (HEVs) in human melanoma lesions
- (2012) Ludovic Martinet et al. OncoImmunology
- The ICOS/ICOSL Pathway Is Required for Optimal Antitumor Responses Mediated by Anti-CTLA-4 Therapy
- (2011) T. Fu et al. CANCER RESEARCH
- Potent Induction of Tumor Immunity by Combining Tumor Cryoablation with Anti-CTLA-4 Therapy
- (2011) R. Waitz et al. CANCER RESEARCH
- Human Solid Tumors Contain High Endothelial Venules: Association with T- and B-Lymphocyte Infiltration and Favorable Prognosis in Breast Cancer
- (2011) L. Martinet et al. CANCER RESEARCH
- Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival
- (2011) Jonathan R. Brody et al. CELL CYCLE
- CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans
- (2011) R. R. Huang et al. CLINICAL CANCER RESEARCH
- Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients
- (2011) Reinhart Speeckaert et al. EUROPEAN JOURNAL OF CANCER
- Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes
- (2011) Rafael Carretero et al. INTERNATIONAL JOURNAL OF CANCER
- The Programmed Death-1 Ligand 1:B7-1 Pathway Restrains Diabetogenic Effector T Cells In Vivo
- (2011) A. M. Paterson et al. JOURNAL OF IMMUNOLOGY
- MART-1- and gp100-Expressing and -Non-Expressing Melanoma Cells Are Equally Proliferative in Tumors and Clonogenic In Vitro
- (2011) Mariana Aris et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Normalization of the Vasculature for Treatment of Cancer and Other Diseases
- (2011) Shom Goel et al. PHYSIOLOGICAL REVIEWS
- Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
- (2011) J. Yuan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance
- (2010) J.-J. Park et al. BLOOD
- Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma
- (2010) Ryosuke Hino et al. CANCER
- Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
- (2010) Geoffrey Y. Ku et al. CANCER
- Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer
- (2010) R. K. Shrimali et al. CANCER RESEARCH
- Imaging of CTLA4 Blockade-Induced Cell Replication with 18F-FLT PET in Patients with Advanced Melanoma Treated with Tremelimumab
- (2010) A. Ribas et al. JOURNAL OF NUCLEAR MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
- (2010) M. A. Curran et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Vaccination with dendritic cells charged with apoptotic/necrotic B16 melanoma induces the formation of subcutaneous lymphoid tissue
- (2010) Soledad Mac Keon et al. VACCINE
- Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment
- (2009) H. Harlin et al. CANCER RESEARCH
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
- (2009) Loise M. Francisco et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
- (2009) Karl S. Peggs et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signal
- (2009) Brian T Fife et al. NATURE IMMUNOLOGY
- Anti-CTLA-4 therapy results in higher CD4+ICOShiT cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues
- (2009) Hong Chen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells
- (2008) T. Azuma et al. BLOOD
- Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma
- (2008) Sergio A. Quezada et al. JOURNAL OF EXPERIMENTAL MEDICINE
- A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10 -1082 promoter genotype as predictor of disease progression
- (2008) Erika M von Euw et al. Journal of Translational Medicine
- Vascular normalization in Rgs5-deficient tumours promotes immune destruction
- (2008) Juliana Hamzah et al. NATURE
- Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
- (2008) F. S. Hodi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CTLA-4 blockade increases IFN -producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients
- (2008) C. I. Liakou et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Selective expansion of a subset of exhausted CD8 T cells by PD-L1 blockade
- (2008) S. D. Blackburn et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now